Riluzolum

compositum chemicum
Esculaap4.svg
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.
Riluzolum
Cognitores
ChemSpider 4892
PubChem 5070
DrugBank DB00740
Natura chemica
Riluzolum
Riluzolum
Formula summarum C
8
H
5
F
3
N
2
OS
Massa molaris 234.199 g/mol
Natura pharmacologica
Codex ATC N07XX02 (WHO)
Tempus semivitae biologicum 9-15 horae
Metabolismus iecore (hepaticus)
Substratum enzymi CYP1A2
Excretio renibus: 90%
Ad usum therapeuticum
Applicatio per os

Riluzolum est medicamentum in sclerose laterali amyotrophica[1] tractando.

Natura RiluzoliRecensere

Natura chemicaRecensere

Riluzolum est (IUPAC) 6-(tri-fluor-methoxy)-1,3-benzothiazolum-2-aminum.

Massa molaris est 234.199 g/mol.

Natura pharmacologicaRecensere

PharmacodynamicaRecensere

Adhuc machinatio effectuum exacta vacat. Videtur Riluzolum per canales ionticos natrii liberationem glutamati ex terminis tractuum corticoefferentium (imprimis tractus corticospinalis[2]) inhibere.

PharmacocineticaRecensere

Excretio est per imprimis urinas.

Effectus RiluzoliRecensere

Effectus secundariiRecensere

Exempli (!) sunt:

Nexus interni

NotaeRecensere

  1. Miller R. G., Mitchell J. D., Moore D. H. (Mar 2012). "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)". The Cochrane database of systematic reviews (3): )CD001447 
  2. Gorges M., Del Tredici K., Dreyhaupt J., Braak H., Ludolph A. C., Müller H. P., Kassubek J. (Oct 2018). "Corticoefferent pathology distribution in amyotrophic lateral sclerosis: in vivo evidence from a meta-analysis of diffusion tensor imaging data". Scientific reports 8 (1): 15389